– USA, TX – Constellation Healthcare Technologies, Inc., the US-based healthcare services and technology company, is pleased to announce the appointment of Dr. Shawn Zimberg to the board as a non-executive director with immediate effect.
Dr. Zimberg is a Board Certified Radiation Oncologist and the Medical Director of Advanced Radiation Centers of New York, a division of Integrated Medical Professionals, PLLC for whom Dr. Zimberg has served on the board of directors since July 2006. Dr. Zimberg is a leading expert in his field and performed his Radiation Oncology residency at the renowned Memorial Sloan-Kettering Cancer Center in New York where he was chosen to receive the American Cancer Society’s Clinical Fellowship award. Dr. Zimberg is widely published in the Oncology field. In addition, in 2014, he was one of the founding partners of Evolution Ventures LLC, a merchant and investment bank focused on life sciences, biotechnology and healthcare and wellness industries.
Paul Parmar, Chief Executive Officer of Constellation commented: “I welcome Dr Zimberg to our Board. He is a highly respected physician and entrepreneur. His addition will help us greatly as we pursue our strategy of being one of the leading healthcare services and technology businesses in the U.S.. Constellation will benefit from his medical insight, especially in the billing and practice management verticals of our business. Constellation will also gain from Dr. Zimberg’s broader knowledge of the U.S. healthcare sector, its pressure points and how the Company can optimise its positioning in-front of the medical community. Dr Zimberg also brings experience as a founding partner of a dedicated healthcare investment bank in the U.S.”.
- Disclaimer - News, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.
Comments are closed.